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Abstract
Systemic hypertension is a highly prevalent potentially modifiable cardiovascular risk factor. Imaging plays an
important role in the diagnosis of underlying causes for hypertension, in assessing cardiovascular complications of
hypertension, and in understanding the pathophysiology of the disease process. Cardiovascular magnetic resonance
(CMR) provides accurate and reproducible measures of ventricular volumes, mass, function and haemodynamics as
well as uniquely allowing tissue characterization of diffuse and focal fibrosis. In addition, CMR is well suited for
exclusion of common secondary causes for hypertension. We review the current and emerging clinical and research
applications of CMR in hypertension.
Review
Systemic hypertension is a highly prevalent [1] chronic dis-
ease, known to be a significant cardiovascular risk factor
[2,3]. Longstanding hypertension causes significant dam-
age to several organs such as the brain, eye, kidney and
heart. Features of hypertensive heart disease include left
ventricular hypertrophy (LVH), diastolic and eventually
systolic heart failure.
A number of imaging techniques are available in the
assessment of hypertension, including echocardiography,
cardiovascular magnetic resonance (CMR), cardiac com-
puted tomography (CCT) and cardiac scintigraphy. 2D
echocardiography is widely available and extensive litera-
ture supports its indication for left ventricular (LV) mass
measurement. This technique can quantify global and
regional systolic function, as well as diastolic function. 3D
echocardiography has partially overcome problems with
accuracy and reproducibility, while difficulties due to poor
acoustic windows and attenuation still persist. CCT has a
high negative predictive value for ruling out coronary artery
disease and it is also appropriate for ventricular mass and
volume measurement and for assessing vascular disease,
while more extensive research is needed before its use for
myocardial tissue characterization can be promoted. Mod-
ern CTscanners generate significantly lower doses of ioniz-
ing radiation, but these are not widely available and issues
with the use of nephrotoxic contrast still remain. Equally,
scintigraphic techniques can be used in the assessment of
hypertensive heart disease but their use is greatly limited
by the limited spatial resolution and thus limited accuracy
in determining LV mass. Thus, CMR appears as the one
technique to provide a comprehensive assessment of
hypertensive cardiovascular disease, including accurate
and reproducible measurement of biventricular function
and volumes, the possibility of serial evaluation, assess-
ment of valvular disease and vascular pathology, myocar-
dial perfusion and tissue characterization.
Cardiac specific sequences are usually implemented in
1.5 T scanners, though 3 T and 1 T open scanners can
be also used. They all yield good image quality with high
spatial resolution. Steady state free precession (SSFP)
cines, phase contrast sequences, T2-weighted short-tau
inversion recovery (STIR), T1- and T2-weighted fast
spin-echo, perfusion and myocardial late gadolinium en-
hancement (LGE) sequences along with 3D-magnetic
resonance angiography (MRA), are the most widely used
sequences in hypertension. Other CMR techniques such
as spectroscopy, myocardial tagging, T1 relaxometry-
based techniques and myocardial velocity mapping could
be useful in the future though at present they are limited
to the research arena. The utility and advantages of
CMR in the characterization of hypertensive cardiac and
vascular disease, as well as in detection of secondary
hypertension, are reviewed below.
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cardiovascular system
Longstanding hypertension has deleterious effects on
several target organs, including heart, brain, kidneys, eyes
and vessels. Regarding the cardiovascular system, hyperten-
sive heart diseases includes left ventricular hypertrophy,
myocardial fibrosis, diastolic prior to systolic ventricular
dysfunction and heart failure, atrial myopathy, atrial fibrilla-
tion, microangiopathy with decreased coronary reserve, and
development of epicardial coronary stenoses [4]. With
regard to the vascular system, the main findings are endo-
thelial dysfunction, remodelling of the small and large arter-
ies with reduced dilatation capability, and generalized
atherosclerotic changes including the development of sten-
oses and aneurysms.
CMR has a unique potential to visualize and assess all
of these alterations in hypertensive patients, leading to
an accurate diagnosis.
Indications and protocol for CMR in hypertension
According to the Joint National Committee VII report on
the prevention, detection, evaluation and therapy of hyper-
tension (JNC-VII) [5], two of the objectives in the manage-
ment of hypertensive patients are to assess target organ
damage and to detect identifiable causes of hypertension.
In both, CMR can be useful though no specific indications
for this imaging technique in hypertensive heart disease
have been established so far and no information regarding
CMR is provided in the above mentioned report.
The 2007 ESH/ESC guidelines [6] recommend total car-
diovascular risk be evaluated in each patient to decide
about important aspects of treatment such as the threshold
at which to commence drug administration, the target
blood pressure to be reached, the use of drug combinations
as the initial treatment step, and the possible addition of
other agents to treatment. According to these guidelines,
the recommended imaging technique when a more sensi-
tive detection of left ventricular hypertrophy than that pro-
vided by ECG is needed is echocardiography, particularly in
patients in whom organ damage is not detected by ECG
and in the elderly in whom cardiac hypertrophy is frequent.
These guidelines indicate that other imaging techniques
such as CMR should be reserved for specific indications
which are unfortunately not summarised in the text. Also,
as discussed in greater detail below, 3D-gadolinium
enhanced MR angiography is considered the imaging tech-
nique of choice for investigating renovascular hypertension,
while MR imaging is also considered a good option to
localize phaeochromocytoma and primary aldosteronism
once an endocrine diagnosis has been made. In the 2009
Reappraisal of European guidelines on hypertension man-
agement [7], the predictive value of both ECG and echocar-
diography were acknowledged with new additional
evidence provided, while no specific recommendation was
done on the use of CMR. Finally, in the 2010 ACCF/ACR/
AHA/NASCI/SCMR Expert Consensus Document [8] no
information regarding the usefulness of CMR in hyperten-
sion was included.
A proposed standard CMR protocol in hypertension is
depicted in Figure 1. In brief, the protocol includes a trans-
axial set of SSFP or black blood fast spin echo images
through the chest. If necessary also coronal and sagittal
orientations can be acquired. Next, high spatial resolution
SSFP cine sequences are taken in three long axis views (2
chamber, 4 chamber and LV outflow tract) and in a short
axis stack from the atrioventricular valves through the
apex. There images are eventually used for ventricular
volume and mass measurements. An SSFP cine in oblique
sagittal of the aorta should also be acquired to rule out
aortic coarctation. If any sign of coarctation is seen, black
blood high resolution turbo spin echo (TSE) sequences
should be acquired, as well as velocity-encoded cines at
the level of the coarctation and at the diaphragmatic level
followed by 3D-MRA. Thereafter, T1W, T2W, in-phase
and out-of-phase pre-contrast VIBE adrenal imaging and
3D-MRA of the renal arteries is performed. Finally, 10
minutes after this last acquisition, late gadolinium
enhancement (LGE) myocardial imaging should be
acquired in the same views as the previously acquired cine
sequences.
Value of CMR in the assessment of hypertensive
cardiovascular disease
Both the heart and the aorta are target organs of systemic
hypertension. Hypertensive heart disease is characterized
by LVH, left atrial dilatation, myocardial fibrosis, diastolic
prior to systolic dysfunction, and increased incidence of
coronary artery disease. Hypertensive vascular disease man-
ifests as aortic wall pathology such as increased prevalence
of atheromatous plaques and higher risk of aneurysm,
dissection, penetrating ulcer, intramural hematoma or per-
ipheral obstructive disease.
Measurement of ventricular dimensions, geometry and
systolic function
The Framingham Study showed that increases in LV
mass are associated with significant increments in car-
diovascular morbidity and mortality independent of the
presence of coronary artery disease, systemic hyperten-
sion or other cardiovascular risk factors [2,9], with a
three-fold increase in mortality both in patients with
[2,10] and without [11] these conditions. For these rea-
sons, the JNC VII report [5] recommends more intensive
management in patients with LVH.
Electrocardiographic criteria of LVH have been in use
for several decades [12,13] but these criteria were mostly
validated against M-mode echocardiography [14] and
lacked sensitivity for LVH. They have been recently
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accuracy. At present, imaging techniques such as echo-
cardiography and CMR are preferred for detecting LVH.
Implementation of echocardiography in its M-mode and
especially 2D modalities dramatically changed cardiac as-
sessment. This technique has great advantages such as
availability, safety and price, for which it is considered the
first line imaging technique in the assessment of heart
dimensions and function. Nonetheless, it has several sig-
nificant limitations such as its dependency on observer, pa-
tient anatomy and position, problems with acoustic
window and with attenuation. M-mode echocardiography
has been widely used in the past but, due to the need for
geometric assumptions, its accuracy and reproducibility
are very low [16]. More recently, accurate and reprodu-
cible 2D echocardiography techniques to measure
volumes and mass based on Simpson’s rule have
attained widespread use, though they still entail geomet-
ric assumptions that cause inaccuracy especially in
dilated, deformed ventricles [17]. The advent of three-
dimensional echocardiography, which does not require
geometric assumptions, has produced measurements
comparable to CMR [18], with good accuracy and repro-
ducibility. However, numerous limitations remain such
as poor acoustic windows and attenuation, as well as the
need for experienced observers.
Figure 1 Time-line figure for the proposed standard CMR protocol in hypertension.
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CMR is currently considered the gold standard for the
measurement of right and left ventricular volumes, mass
and function, boasting high accuracy and reproducibility
[17,19]. Reference values have been published for all these
parameters [20]. With modern SSFP cine sequences com-
bined with parallel processing techniques, a whole con-
tiguous ventricular short axis cine stack can be acquired in
potentially just one breath-hold. In one study, in addition
to accurate assessments of ventricular volumes and func-
tion, an overall assessment of cardiac and extracardiac
(thoracic) anatomy can be obtained. Published data reveal
an intraobserver and interobserver variability of 2.0–7.4%
and 3.3–7.7%, respectively [19]. These values are lower
than those obtained with echocardiography, conferring
lower sample size requirements for intervention studies in
several conditions such as heart failure or hypertension
and thereby also dramatically reducing study costs [21].
Importantly, recent data have shown that LV mass
should be indexed to height to the power of 1.7, which is
more sensitive than body surface area indexed LV-mass in
identifying obesity-related LVH, and appears to be most
consistently associated with cardiovascular events and all-
cause mortality [22].
LV geometry
CMR can not only quantify LV mass but also assess the
pattern of hypertrophy, that is, LV geometry, which may
have prognostic importance. The assessment of LV remod-
elling by echocardiography has the same limitations as
related above. By contrast, the unfettered full myocardial
coverage of CMR offers a precise measurement of LV wall
thickness [23] and geometry and has provided other mea-
sures of LV remodelling and hypertrophy including the
relative wall mass, which is the conceptual equivalent of
the echocardiogram-derived relative wall thickness [24,25].
The relative wall mass is calculated by dividing the LV mass
by the LV end-diastolic volume, and effectively indexes
ventricular wall thickness to cavity size. Thus, concentric or
eccentric LV hypertrophy (increased LV mass with relative
wall mass above or below the cut-off value of 1.16, respect-
ively) and concentric remodelling (normal LV mass with
relative wall mass above 1.16) all predict an increased inci-
dence of cardiovascular disease, but concentric hypertrophy
has consistently been shown to be the condition which
most markedly increases risk [26]. In addition, differences
in the prevalence of LVH and different ventricular remodel-
ling patterns have been identified in various ethnic groups
and should be taken into account when evaluating cardio-
vascular risk in these populations [27].
CMR and LV function
Ejection fraction as well as endocardial and mid-wall
fractional shortening have all been proposed as possible
additional predictors of cardiovascular events in hyper-
tension [28], though CMR has recently shown that mid-
wall fractional shortening has limitations related to
appropriateness for assessment of cardiac pumping, and
dependency of LV wall thickness [29]. While conven-
tional high temporal resolution cine sequences allow for
an accurate assessment of the overall ventricular per-
formance, if the aim is to study regional function, de-
formation or strain measured by CMR tissue tagging is
indicated [30]. A number of recent studies have shown
that though global ejection fraction is preserved in the
early stages of hypertension, mid-wall shortening mea-
sured by echocardiography and circumferential strain
measured by CMR tagging are depressed, with a reduc-
tion that appears to be associated with raised blood pres-
sure [31], and, furthermore, a substantial regional
intramyocardial strain heterogeneity can be observed,
with most severely depressed strain patterns in the
septum [32]. Myocardial tagging could thus be applied to
characterize the physiological contraction cycle, to deter-
mine pathophysiological changes of rotation, longitudinal
and circumferential shortening, and to follow-up changes
of LV wall motion in hypertensive LVH.
CMR in hypertrophy regression studies
While LVH of whatever aetiology confers increased car-
diovascular risk, regression of LVH has been shown to
be associated with decreased risk [33]. Due to its high
reproducibility, CMR has been used for measurement of
ventricular mass regression in a number of intervention
studies in hypertension. These include a LIFE substudy
in which contribution of high blood pressure to ventricu-
lar remodelling was assessed [34]; the TELMAR study
[35], which compared the effect of telmisartan to meto-
prolol on LVH in patients with uncontrolled hyperten-
sion; the LVH-4E [36], in which eplerenone was
compared to enalapril or a combination of both in LVH
regression in hypertensive patients; the ALIVE study
[37], in which benazepril with either amlodipine or a di-
uretic was tested; and recently the ALLAY trial [38], in
which aliskiren, a direct renin inhibitor, was shown to be
as effective as losartan in reducing LV mass. Figure 2
illustrates a case of hypertrophy regression in a 41 yo
woman with resistant hypertension, 1 year after excision
of an adrenal adenoma.
Differential diagnosis with other causes of LVH
Determination of the aetiology of LVH is a common clinical
problem that can be challenging, because pathological
forms of LVH present with overlapping cardiac hypertrophy
phenotypes. A number of other conditions can mimic LVH
such as infiltrative diseases, hypertrophic cardiomyopathy
(HCM), Fabry’s disease, cardiac sarcoidosis, aortic stenosis,
and exercise-induced ventricular hypertrophy or athlete’s
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diagnosis, other conditions can be difficult. The unique cap-
acity of CMR to non-invasively characterise myocardial
tissue represents an important advantage over other non-
invasive imaging modalities. Regarding infiltrative condi-
tions, a specific pattern of late gadolinium enhancement has
been described for amyloid heart disease [39,40] with good
sensitivity of 80%, specificity of 94% and positive predictive
value of 92% that has simplified the differential diagnosis.
In a recently published study multiparametric CMR im-
aging was used to differentiate hypertensive LVH from
HCM and distinctive hypertrophic phenotypes were detect-
able [41]. While hypertensive patients had reduced ejection
fraction, increased cardiac chamber volumes, increased LV
wall stress and reduced anteroseptal systolic strains,
patients with HCM had supernormal ejection fraction,
reduced LV wall stress, decreased longitudinal systolic
strain and fibrosis. Logistic regression analysis identified
increased LV wall stress as the hallmark of hypertension
(odds ratio 1.2, SE 0.01, specificity 80%, sensitivity 65.5%,
diagnostic accuracy 72.9%), while HCM was best character-
ized by reduced total longitudinal strain (odds ratio 1.3, SE
0.02, specificity 89.3%, sensitivity 78.6%, diagnostic accuracy
78.6%).
Also, athlete’s heart can be distinguished from other
forms of pathological hypertrophy with the CMR-derived
diastolic wall-to-volume ratio [42]. A cut-off value of less
than 0.15 mm×m
2 /ml, is said to have a 99% specificity for
sport-related LVH. However this finding requires further
validation and confirmation in larger cohorts. Figure 3
depicts the differential diagnosis of LV hypertrophy.
CMR and detection of myocardial fibrosis
Animal and human studies have shown that in hyperten-
sive LVH accumulation of type I and III collagen fibres
occurs both in the interventricular septum and free wall
[43]. This increase in collagen content appears to be a fre-
quent feature of LVH, regardless of its cause and just
depending on the severity of LV remodeling [44]. Myocar-
dial fibrosis can be focal, also called reparative or replace-
ment fibrosis [45], or diffuse, also known as interstitial
fibrosis and is the most typical pattern in hypertensive
heart disease. Fibrosis would cause myocardial stiffness
and subsequent changes in ventricular function, electrical
Figure 2 Regression of hypertrophy after excision of an adrenal adenoma. Panel A shows a baseline short axis stack of a 41 year old female
patient with resistant hypertension, LV mass=232 g. Panel B shows the same patient 1 year after excision of an adrenal adenoma, LV
mass=154 g.
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affect prognosis [46].
Interest has recently grown in the possibility of assessing
the degree of myocardial fibrosis in order to refine the abil-
ity to predict outcome in hypertensive LVH, and several
methods have been proposed. Serum markers of fibrosis
have been proposed, mainly the carboxyterminal propep-
tide of procollagen type I (PIP), a marker of collagen syn-
thesis whose serum levels correlate with the presence of
severe myocardial fibrosis [47]. Collagen markers however
lack specificity as they are only partly derived from the heart
[48]. Among the imaging techniques, a simple Doppler-
derived index such as the mitral inflow deceleration
time has been used to calculate myocardial stiffness as
an indirect marker of myocardial fibrosis [49]. Echocar-
diographic analysis of cyclic variation of the backscatter
signal has also been proposed used for this purpose and
shown to vary according to serum PIP levels [50] and dia-
stolic function [51]. However, echocardiography only pro-
vides an indirect assessment of fibrosis, and is plagued
with reproducibility problems, attenuation, artefacts and
difficulty in achieving correct alignment of the beam, espe-
cially for Doppler-based techniques. Speckle tracking has
partially overcome these limitations as it does not depend
on the correct alignment of the ultrasound beam, but it
still requires high quality echocardiographic images for
adequate endocardial border delineation.
LGE-CMR is able to show focal myocardial fibrosis, as
demonstrated in several conditions including hypertension
[39,44,52-54], a case of which is shown in Figure 4. In this
respect one study has shown that 45% of patients with
arterial hypertension had myocardial LGE, which appears
to be related to both myocardial interstitial fibrosis and
coronary microangiopathy [55]. The main limiting factor
of using LGE-CMR in hypertensive patients, though, is
that the fibrotic process is often diffuse. Diffuse myocardial
fibrosis is missed by LGE-CMR because LGE relies on
relative differences in signal intensities and employs the
myocardium with lowest signal intensity as a reference for
normality, regardless of the degree of fibrosis contained in
it. In this regard, the T1 mapping techniques have an
advantage over LGE-CMR as they are based on images
produced with a standardized scale calculating the relax-
ation time of each pixel within a parametric image. Each
tissue exhibits a characteristic T1 relaxation time at a
selected magnetic field strength that depends on tissue
composition and, thus, deviation from normal ranges
could be used to detect and quantify pathological pro-
cesses such as hypertensive difuse myocardial fibrosis.
Early T1 mapping techniques were very time consuming.
A Look-Locker sequence [39,56-58] consisting of a gradi-
ent echo cine sequence with a nonslice selective inversion
pulse after an R wave followed by a segmented gradient
echo acquisition. This was applied both before and at least
two times, from five minutes after contrast administration.
Mean signal intensities were plotted against the delay after
the inversion pulse. The points were then fit with a non-
linear least squares procedure and T1 values were derived
from the fit parameters. Finally, a myocardial gadolinium
contrast partition coefficient would be calculated from the
change of relaxation rate after contrast injection. More
recently, the MOdified Look-Locker Inversion recovery
pulse sequence (MOLLI) was developed that merged
images from three consecutive inversion-recovery
experiments into one data set, generating single-breath-
hold single-slice T1 maps of the myocardium [59-61]. A
Shortened MOdified Look-Locker Inversion recovery
(ShMOLLI) sequence [62] has also been recently tested
Figure 3 Differential diagnosis of LVH. Diastolic SSFP cines (above) and LGE-sequences (below) in the 4-chamber view of several types of
hypertrophy are depicted. From left to right: hypertensive cardiomyopathy, hypertrophic cardiomyopathy, Fabry’s disease, cardiac amyloid
infiltration and cardiac sarcoidosis. Different gadolinium myocardial enhancement patterns (arrows) are shown corresponding to each condition:
very subtle focal intramyocardial fibrosis in the basal septum of a hypertensive cardiomyopathy patient, confluent intramyocardial fibrosis in a case
of hypertrophic cardiomyopathy, subendocardial fibrosis in the lateral wall in a case of Fabry’s disease, global difuse subendocardial fibrosis in
amyloid cardiomyopathy and subendocardial/intramyocardial/subepicardial fibrosis in a case of sarcoidois.
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ments within a single shortened breath-hold. These
sequences hold promise for the detection of interstitial
myocardial fibrosis in patients with hypertensive heart
disease.
CMR in the assessment of diastolic performance, atrial
dimensions and function
In longstanding systemic hypertension, diastolic heart fail-
ure, characterized by heart failure symptoms, preserved
ejection fraction and diastolic dysfunction, often develops
and carries an ominous prognosis [64]. The technique of
choice for noninvasive assessment of diastolic function is
echocardiography, mainly flow Doppler and tissue Doppler
imaging. The assessment of diastolic function with CMR
requires the use of high temporal resolution sequences.
Several techniques have been used for this purpose, such
as quantification of ventricular volume change over time
in the cardiac cycle using retrospective gating, which pro-
vides parameters such as: atrial filling ratios, peak diastolic
filling rate and time to peak filling rate; analysis of three di-
mensional myocardial strains with tissue tagging gated to
diastole, and mitral inflow velocity curves obtained with
phase contrast sequences. A novel CMR-derived index -
diastolic volume recovery, calculated as the percentage
proportion of diastole required for recovery of 80% stroke
volume, has been recently shown to yield the best per-
formance versus echocardiography to detect diastolic dys-
function [65]. Still, the superior temporal resolution and
ease of assessment of echocardiography in its multiple
variants renders it by far the technique of choice for
diastolic function assessment.
Atrial dilatation correlates with the chronicity of hyper-
tension and with the severity of diastolic dysfunction. Im-
portantly, atrial size is independently associated with
cardiovascular morbidity and mortality [66] and with the
development of atrial fibrillation [67]. While echocardiog-
raphy calculates volumes using geometric assumptions,
which due to the shape of the atria are prone to be highly
inaccurate, CMR provides an accurate and reproducible
measure of atrial volume by means of a 3D approach, in all
types of patients [68]. Reference values of left atrial dimen-
sions and volume with CMR are now available [69].
CMR for the detection of coronary artery disease
Assessing coronary disease in the hypertensive patient with
chest pain is particularly challenging. Systemic hyperten-
sion is an established risk factor for epicardial coronary
artery disease [70,71], but, in the setting of hypertensive
LVH, small vessel disease with impaired myocardial perfu-
sion reserve can be responsible for myocardial ischemia
without significant coronary artery stenosis by coronary
Figure 4 Focal myocardial fibrosis in a hypertensive patient. LGE-sequences in a 63 year old female patient with longstanding hypertension
are shown. The arrows show an area of intramyocardial late gadolinium enhancement in the basal and mid inferoseptal and inferolateral
segments. This is not the most typical fibrosis pattern in hypertension, which is usually diffuse.
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sion CMR may non-invasively differentiate patients with
small vessel disease from those with epicardial coronary
artery disease, based on the temporal and spatial extent of
the perfusion deficits. In small vessel disease perfusion def-
icits are usually diffuse, circumferential, affecting ≤ 1/3 of
the wall thickness and with shorter persistence (≤ 5 heart-
beats) than those in patients with significant epicardial cor-
onary disease [73-75]. This differentiation is important
with respect to therapy and also to prognosis [76].
Saturation-recovery sequences acquired on first pass of
gadolinium during vasodilator stress with either adenosine
or dipyridamole have a good diagnostic yield for detection
of ischaemia and significant epicardial coronary disease
[77-79], while late gadolinium enhancement CMR is con-
sidered the best technique for localization and quantifica-
tion of myocardial necrosis [80,81].
CMR in the assessment of aortic and peripheral vascular
disease
Systemic hypertension is an established risk factor for aor-
tic and peripheral vascular disease. On the other hand, the
relationship between cardiovascular risk factors including
hypertension [82,83] and visualization of atheroma plaques
in the aorta, as well as their prognostic value [84], has been
reported. CMR can provide a comprehensive assessment
of aortic anatomy and function, including not only the
assessment and follow-up of aortic wall syndromes such as
aneurysm, dissection or intramural hematoma, but also
evaluation and quantification of the atherosclerotic plaque
volume, composition, biological activity, and quantification
of aortic functional parameters such as stiffness, distensi-
bility and pulse wave velocity. Figure 5 illustrates the utility
of T1WTSE and 3D MRA sequences in the assessment of
a type A aortic dissection and aortic aneurysm.
Plaque imaging may be important as part of risk
assessment, which may alter thresholds for treatment, and
may be of utility in plaque-regression studies. It has been
shown that patients with prior major cardiovascular events
have greater plaque burden and plaque eccentricity [85].
Likewise, the presence of aortic atheroma in a particular
patient indicates a higher risk of a cardiovascular event
than could be expected from the Framingham score alone,
which was not designed to detect atherosclerotic plaques
[86]. Thus, reasonably, assessment of sub-clinical athero-
sclerosis could be considered in persons at intermediate
risk by the Framingham score, in whom the presence of
aortic atheroma might cause a change in therapy.
Black blood CMR imaging is highly accurate and repro-
ducible for assessment and volumetric quantification of
atheroma plaques in the carotid arteries [87] and aorta
[88,89], as illustrated in Figure 6. Recent MR technological
improvements allow fast, accurate, and reproducible plaque
imaging. Interestingly, multicontrast CMR is able to assess
plaque composition, and markers of plaque inflammation
and neovascularisation, such as superparamagnetic phago-
cytosable nanoparticles [90], have been developed for
in vivo plaque imaging. Protocols for assessing aortic wall
anatomy and structure usually include high resolution T1
and T2-weighted TSE and STIR sequences and/or 3D angi-
ography. Images obtained are eventually processed in order
to quantify plaque volume and characterize plaque com-
position, which have been histologically validated [91,92].
A functional assessment of the aorta can be carried
out with CMR by acquiring flow-sensitive and cine
sequences. Blood flow affects arterial remodelling, and
decreased arterial distensibility is an early manifestation
of adverse structural and functional changes within the
vessel wall [87]. Furthermore, atherosclerosis, as well as
endothelial biology, depends on arterial wall shear stress.
Flow-sensitive 4D-MRI, which allows the depiction of
3D morphology as well as the acquisition of time-
resolved blood flow velocities in 3 directions, provides
information regarding the regional differences in abso-
lute wall shear stress and oscillatory shear index. This
may help explain the physiopathology of atherosclerotic
lesions, mainly how they develop and progress predom-
inantly at specific locations in the aorta [93].
CMR in the detection of Secondary causes of
Hypertension
Resistant hypertension is defined as failure to achieve tar-
get blood pressure when a patient adheres to optimal
doses of three or more antihypertensive drugs usually
including a diuretic [5]. The prevalence of resistant hyper-
tension may range from 5% in general practitioner clinics
to more than 50% in specialist hypertension clinics [94].
Secondary causes of hypertension are common in patients
with resistant hypertension and recognition of these iden-
tifiable causes is important in order to offer the patient the
most adequate and effective management and thereby
improve prognosis by preventing the chronic complica-
tions of hypertension. Accordingly, the JNC VII report [5]
recommends more intensive management if clinical data,
physical signs or routine laboratory tests suggest secondary
hypertension.
Common secondary causes are renal parenchymal dis-
ease, renal arterial disease, primary hyperaldosteronism
and obstructive sleep apnoea. Less common causes are
Cushing’s syndrome, phaeochromocytoma, thyroid dis-
ease, aortic coarctation, and intracranial tumours. The
main physiopathological mechanisms are depicted in
Figure 7. There are a number of imaging techniques,
along with laboratory tests, that can be carried out to
rule out secondary hypertension and some of them, sum-
marized below, can be assessed in the course of a CMR
study in a hypertensive patient in whom the clinical sus-
picion is high.
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This may be present in up to 35% of patients with resistant
hypertension [95]. Of all cases of renal artery stenosis, 90%
are of atherosclerotic origin [96] and 10% are due to fibro-
muscular dysplasia. The latter is considered a systemic dis-
ease in which renal arteries are the most frequent
localization, though other arteries may also be involved.
This condition develops mainly in women below 50 years
of age, involves the mid and distal renal arteries and
branchpoints, and treatment is angioplasty in most cases.
On the other hand, atherosclerotic renal artery stenosis is
usually found in patients with widespread atheromatous
disease, clinical presentation includes severe hypertension,
recurrent flash pulmonary oedema, progressive renal dys-
function and a higher incidence of adverse cardiovascular
events [97]. Recommended management for atherosclerotic
renal artery stenosis is medical therapy, while angioplasty
has been traditionally reserved only to protect renal func-
tion but a recent study has shown substantial risks and no
evidence of a worthwhile clinical benefit from revasculari-
zation [98]. The detection of bilateral renal artery stenosis
can nevertheless guide pharmacotherapy.
Screening techniques for renal artery stenosis are war-
ranted when there is a high level of suspicion (young
women and older patients). There are a number of non-
invasive tests available including duplex ultrasound, which
provides anatomical information as well as flow velocity
quantification and assessment of pressure wave morph-
ology, CT-angiography, and nuclear captopril renal scintig-
raphy. The gold standard diagnostic test has traditionally
been intra-arterial digital subtraction contrast angiography
but this technique is invasive and not free of complications
[94]. While for suspected fibromuscular dysplasia it may
be reasonable to proceed directly to renal angiography, for
most patients with suspected atherosclerotic disease this
technique should be limited to those patients willing to
undergo revascularization, the benefit of which is increas-
ingly questioned. Magnetic resonance angiography (MRA)
Figure 6 Aortic wall volume measurement. The middle picture show T2W-TSE continuous transverse slices of the thoracic aorta as piloted
from the left picture. The right picture shows the same sequence with regions of interest for volumetric quantification. Arrows indicate the
location of small aortic plaques.
Figure 5 Aortic wall pathology. The left and middle pictures show a T1WTSE and 3D-MRA sequences of a type A aortic dissection, in which the
true (T) and false (F) lumens can be clearly seen. The right picture shows an aortic aneurysm involving the arch and descending thoracic aorta of
a hypertensive patient.
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that also allow for functional characterization of renal artery
stenosis. MRA is highly sensitive for stenosis, but the speci-
ficity can be low and minimal lesions can be characterized
as moderate or high grade [99]. Over the past few years,
technical improvements including high-performance gradi-
ent systems, high parallel-imaging acceleration factors, and
improved surface coil technology have allowed increased
isotropic, sub-millimetre spatial resolution with high signal-
to-noise ratios. By reducing scan and breath-hold time,
these sequences have greatly improved the diagnosis of
renal artery stenosis. Two meta-analyses [100,101] showed
that gadolinium-enhanced 3D MRA has a sensitivity and
specificity of >90%. Finally, the use of new higher-relaxivity
blood-pool contrast agents for combined first-pass and
steady-state imaging in patients with suspected renovascular
hypertension has potential added value. Figure 8 illustrates
the utility of 3D-MRA in a hypertensive patient with severe
left renal artery stenosis in whom the raw images also show
delayed enhancement and atrophic changes on the left
kidney.
In the context of renal artery stenosis, which is usually
associated with a degree of renal impairment, the issue
of nephrogenic systemic fibrosis (NSF) must be consid-
ered prior to administration of gadolinium contrast. NSF
is an extremely rare but important complication of gado-
linium administration, associated with acute renal failure
or severe chronic renal failure due to advanced (glom-
erular filtration rate less than 30 mL/min/1.73 m
2)
chronic kidney disease, but also with other conditions
such as liver failure, liver or kidney transplant, hypercoa-
gulability, deep vein thrombosis and proinflammatory
processes. NSF is a scleroderma-like fibrosing entity
which affects the skin and several organs including
pleura, pericardium, lungs, joints, and striated muscle in-
cluding diaphragm and myocardium [102]. Though the
overall risk in the absence of risk factors is very low, its
incidence appears to be between 1 and 4% when these
are present [8]. Thus, administration of gadolinium in
patients with these conditions must be made if expected
benefits outweigh risks, using a macrocyclic chelate in
the lowest possible dose and avoiding repeat exposure.
Figure 7 Pathophysiology of several secondary causes of hypertension: renovascular hypertension, primary aldosteronism, coarctation
of the aorta, phaeochromocytoma and Cushing’s syndrome.
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stage renal failure should be considered.
Primary hyperaldosteronism (Conn’s syndrome)
This is a much more common cause of hypertension than
p r e v i o u s l yt h o u g h ta n di sp r e s e n ti nu pt o2 0 %o fp a t i e n t s
with resistant hypertension [103]. Given the high incidence
of adrenal incidentalomata, direct imaging is usually not
recommended. Instead, initial biochemical assessment fol-
lowed by imaging (which raises pre-test likelihood and
therefore post-test likelihood ratios in the event of a positive
test) is recommended in hypertensive patients with resistant
hypertension, hypokalemia or features of secondary hyper-
tension. The most frequent cause is adrenal adenoma, and
makes up 65% of cases. Bilateral adrenal hyperplasia is re-
sponsible for 30% of cases and the remainders are due to
adrenal carcinoma or extra-adrenal tumours. While screen-
ing is based on high plasma aldosterone and high plasma al-
dosterone/plasma renin activity ratio and confirmation is
done by demonstrating a high 24-hour urinary aldosterone
in the course of a high dietary sodium intake, MR is indi-
cated for localization of the causative lesion. Most aden-
omas are iso- or hypo-intense relative to the liver on T1-
weighted images and slightly hyperintense on T2-weighted
images, while with chemical shift imaging the signal charac-
teristically decreases on the out-of-phase images. MR has
very high specificity for detecting aldosterone-producing ad-
enomata and sensitivity similar to that of CT imaging [104].
Cushing’s syndrome
The exact prevalence of Cushing’ss y n d r o m ea m o n g s t
patients with resistant hypertension is uncertain, but it is
estimated that approximately 3 to 6% of cases of secondary
hypertension are due to corticosteroid overproduction
[105]. Hypertension in Cushing’s syndrome is significantly
correlated with the duration of hypercortisolism and
results from the interplay between several pathophysio-
logical mechanisms regulating plasma volume, peripheral
vascular resistance and cardiac output. Detection is im-
portant for therapeutic and also for prognostic reasons, as
target organ damage in this condition is more severe than
in primary hypertension [106] and the overall cardiovascu-
lar risk is increased because the disorder is associated with
other concomitant major risk factors such as diabetes mel-
litus, metabolic syndrome and dyslipidemia. Cushing’s syn-
drome may be due to steroid use, ectopic ACTH, pituitary
microadenoma and adrenal adenoma. Initial screening is
carried out with an overnight 1 mg dexamethasone sup-
pression test, which is preferred over measurement of 24-
hour urine free cortisol. In order to differentiate pituitary
dependent syndromes from non-pituitary causes, combin-
ation of a CRH stimulation test with a dexamethasone
suppression test and measurement of ACTH can be done.
Finally, localization, needed before surgical therapy, is
done by MR or CT [107]. If test results indicate an
ACTH-independent lesion, abdominal CT or MR scan-
ning are indicated. Figure 9 shows an MR study of an ad-
renal adenoma visible on the left adrenal gland, including
T1W, T1W-FS and VIBE sequences (top), and in-phase
and out-phase sequences (bottom). If the process is ACTH
dependent, a high-dose dexamethasone suppression test
combined with cranial MR may aid in localizing the lesion
[108]. Hypertension in Cushing’s syndrome usually
resolves with surgical removal of the tumour, but some
patients require pharmacological anti-hypertensive treat-
ment both pre- and post-operatively.
Figure 8 3D-MRA of a 66 year old hypertensive patient with increased plasma creatinine on ACE-inhibitor therapy. The study shows
severe left renal artery stenosis. The raw images show delayed enhancement on the left kidney, which also shows atrophic changes.
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This is an unusual but prognostically important secondary
cause of hypertension. Again, the prevalence of this condi-
tion in resistant hypertension is unknown but it is consid-
ered to be up to 0.6% in the general hypertensive
population [109]. Phaeochromocytoma is characterized by
increased blood pressure and blood pressure variability
[110] which constitutes an additional independent risk fac-
tor for cardiovascular morbidity and mortality. Thus,
detection is important for therapeutic and prognostic rea-
sons. Diagnosis is based on measurement of plasma free
metanephrines and of 24-hour urinary catecholamine
levels. Imaging techniques are indicated for localizing and
staging the tumour, but not for tissue characterization as
this tumour can undergo a number of forms of pathologic
degeneration affecting its imaging features. Thus, though
65% of phaeochromocytomas are characteristically solid,
hypervascular masses with low signal intensity on T1-
weighted, high signal intensity on T2-weighted MR images
and enhancement after gadolinium, a wide range of im-
aging appearances can be found, mimicking other lesions
both benign and malignant. For instance, phaeochromocy-
tomas may be dark on T2-weighted images, or they may
include haemorrhagic, cystic, fibrotic and calcific changes,
or they may have so much fat as to be misdiagnosed as an
adenoma. Results on CT and radionuclide imaging can
also be inconsistent.
Aortic coarctation
This congenital defect is present in 0.2% of hypertensive
adults [111]. Coarctation of the aorta imposes significant
afterload on the left ventricle (LV), which results in
increased wall stress and compensatory ventricular
hypertrophy. The mechanism by which hypertension
appears in these patients is not completely understood. Sev-
eral mechanisms have been postulated: mainly the mechan-
ical obstruction hypothesis, the renin-angiotensin–mediated
humoral hypothesis or Goldblatt-type phenomenon and the
neural theory. According to the mechanical obstruction the-
ory, a higher blood pressure is required to maintain flow
through the coarcted segment and collateral vessels. As a
result, the stroke volume ejected into the limited aortic re-
ceptacle produces a higher pressure proximal to the coarc-
tation. This theory, though, fails to explain features such as
the abnormal blood pressure response to exercise after re-
pair, the development of early hypertension in spite of early
effective repair and the development of end-organ dam-
age late after repair [112]. The humoral theory postu-
lates activation of the renin-angiotensin system
secondary to reduction of renal blood flow but plasma
renin activity has not been consistently found to be ele-
vated in these subjects and, while it is reasonable to
hypothesize that an increase in the renine angiotensin
system contributes to hypertension in patients with
coarctation, its role in the development of hypertension
at rest and during exercise after a successful repair is
still unclear [113]. Some studies have suggested reduced
baroreflex sensitivity as a cause of abnormal blood pres-
sure regulation after coarctation repair [114], while the
concomitant effect of other associated cardiac anomalies
and neurohumoral changes that occur in heart failure
cannot be discarded.
Echocardiography, both transthoracic and transoeso-
phageal, is usually the imaging technique of choice for
initial assessment [115], but for further evaluation con-
trast angiography, cardiovascular computed tomography
Figure 9 MR study showing an adrenal adenoma. The upper row shows, from left to right, T1W, T1W-FS and VIBE sequences. The lower row
shows, from left to right, in-phase and out-phase sequences. An adrenal adenoma is visible on the left adrenal gland, with preserved signal
intensity in the T1W-FS sequence and low signal intensity in the out-phase sequence.
Maceira and Mohiaddin Journal of Cardiovascular Magnetic Resonance 2012, 14:28 Page 12 of 17
http://www.jcmr-online.com/14/1/28and CMR have been used [116]. Even though contrast
angiography is still considered the gold standard for
evaluation of aortic coarctation, the use of CMR has
increased over the past few years. The availability of dif-
ferent techniques such as cine sequences, phase contrast
imaging and 3D angiography allow for the accurate and
reproducible description of aortic anatomy, presence of
collaterals and quantification of severity through peak
velocity across the stenosis and amount of collateral
flow, which help in decision making [117]. The ability to
perform serial follow up studies both before and after
repair with no ionising radiation is a distinct advantage
for CMR over CT particularly in this younger cohort of
patients. Figure 10 shows T1W-TSE and 3D-MRA
sequences of two patients with juxtaductal aortic coarc-
tation and significant collateral circulation.
Aortic coarctation is associated with functional aorto-
ventricular disturbances, such as abnormal myocardial
perfusion reserve with sub-endocardial ischaemia, and
increased central aortic stiffness that leads to ascending
aorta dilatation and increased LV mass. These condi-
tions persist after surgery and may contribute to in-
crease cardiovascular mortality and morbidity. Finally,
re-coarctation of the aorta may lead to worsening sys-
temic hypertension, coronary artery disease and/or con-
gestive cardiac failure. CMR follow-up after coarctation
repair will detect re-coarctation as well as those with
aortoventricular disturbances, who require more fre-
quent non-invasive surveillance [118].
Future directions
The unique potential of CMR in hypertensive heart dis-
ease implies a high number of indications to be
developed in the future, both in diagnosis and in risk
stratification of future cardiovascular events. These in-
clude analysis and quantification of regional myocar-
dial mechanics, which will allow detection of subtle
decay in systolic function, detection and quantification
of diffuse myocardial fibrosis, assessment of atrial
mechanics, and assessment and quantification of aortic
flow mechanics.
The prognostic value of measuring diffuse and focal
myocardial fibrosis in predicting future cardiovascular
events such as heart failure or arrhythmias also hold
promise with a potential role for monitoring the
response to antihypertensive, antifibrotic drugs. Para-
meters of atrial function and wall fibrosis should also be
tested for prediction of developing atrial fibrillation.
Conclusions
CMR provides a comprehensive assessment of hyperten-
sive cardiovascular disease. In less than an hour, ven-
tricular and aortic measurements are obtained with high
accuracy and reproducibility, the pathophysiological con-
sequences of hypertension can be assessed and several
quantitative parameters can be obtained with high repro-
ducibility and accuracy that can be of use in the follow
up of these patients. Concurrently, several secondary
causes of hypertension can be ruled out in the same
study. With respect to prognostic assessment, the devel-
opment of T1 mapping sequences for quantification of
myocardial fibrosis might play an important role in the
risk stratification of hypertensive heart disease.
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